Industry
IMMUNOe Research Centers
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 4 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 4
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 4(2)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (4)
Showing 4 of 4 trials
NCT04705831Phase 2Completed
Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection
Role: lead
NCT03576469Phase 4Completed
A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions
Role: lead
NCT03348618Phase 4Unknown
A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
Role: lead
NCT03339778Completed
The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations
Role: lead
All 4 trials loaded